Association between paraoxonase-1 Q192R polymorphism and lung function among Saskatchewan grain handlers

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 901-908

  Takayuki, Seo ^a,e   Pahwa, Punam ^b   McDuffie, Helen H ^b   Shindo, Junichi ^c   Goto, Shuji ^a,e   Hashimoto, Mirai ^d   Ghosh, Sunita ^b   Nakagawa, Kazuko ^a,e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e Division of Pharmacology and Therapeutics   (Japan)

Author keywords

Gene environment interaction; Genetic polymorphism; Grain handlers; Interaction; Lung function; Paraoxonase 1; Smoking

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; INCIDENCE; LUNG FUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; SYMPTOM;

ADULT; AGRICULTURE; ARGININE; ARYLDIALKYLPHOSPHATASE; CEREALS; FORCED EXPIRATORY VOLUME; GLUTAMINE; HUMANS; LUNG; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RESPIRATORY FUNCTION TESTS; SASKATCHEWAN; SMOKING;

EID: 34548762003     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.901     Document Type: Article

References (46)

1. National Collaborating Centre for Chronic Conditions: Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59(Suppl 1), 1-232 (2004).
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J Resak. Crit. Cam Med. 163(5), 1256-1276 (2001).
3. Pahwa P, McDuffie HH, Dosman JA: Longitudinal changes in prevalence of respiratory symptoms among Canadian grain elevator workers. Chest 129(6), 1605-1613 (2006).
4. Pahwa F, Senthilselvan A, McDume HH, Dosman JA: Longitudinal estimates of pulmonary function decline in grain workers. Am. J. Respir. Crit. Care Med. 150(3), 656-662 (1994).
5. Matheson MC, Beake G, Raven J et al.: Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 60(8), 645-651 (2005).
6. Walter R, Gottlieb DJ, O'Connor GT: Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic obstructive lung disease. Environ. Health. Perspect. 108(Suppl. 4), 733-742 (2000).
7. Moira CY, Enarson DA, Kennedy SM: The impact of grain dust on respiratory health. Am. Rev. Respir. Dis. 145, 476-487 (1992).
8. Sandford AJ, Pare PD: Genetic risk factors for chronic obstructive pulmonary disease. Clin. Chest Med. 21(4), 633-643 (2000).
9. Kleeberger SR, Peden D: Gene-environment interactions in asthma and other respiratory diseases. Annu. Rev. Med. 56, 383-400 (2005).
10. He JQ, Connett JE, Anthonisen NR, Pare PD, Sandford AJ: Glutathione S-transferase variants and their interaction with smoking on lung function. Am. J Respir. Crit. Care Med. 170(4), 388-394 (2004).
11. Hang J, Zhou W, Wang X et al.: Microsomal epoxide hydrolase, endotoxin, and lung function decline in cotton textile workers. Am. J. Respir. Crit. Care Med. 171(2), 165-170 (2005).
12. Molfino NA: Genetics of COPD. Chest 125(5), 1929-1940 (2004).
13. Hegab AE, Sakamoto T, Saltoh W et al.: Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 126(6), 1832-1839 (2004).
14. McDuffie HH, Nakagawa K, Pahwa P et al.: Tumor necrosis factor a, and pulmonary function in Saskatchewan grain handlers. J. Occup. Environ. Med. 48(5), 505-512 (2006).
15. Li WF, Costa LG, Richter RJ et al.: Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10(9), 767-779 (2000).
16. Costa LG, Cole TB, Vitalone A, Furlong CE: Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 352(1-2), 37-47 (2005).
17. Aviram M, Hardak E, Vaya J et al.: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxicles in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101(21), 2510-2517 (2000).
18. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P: Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26(7),1545-1550 (2006).
19. Draganov DI, La Du BN: Pharmacogenetics of paraoxonases: a brief review. Naunyn. Schmiedebergs. Arch, Pharmacol. 369(1), 78-88 (2004).
20. La Du BN, Aviram M, Billecke S et al.: On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 119-120, 379-388 (1999).
21. Wu A, Hinds CJ, Thiemermann C: High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21(3), 210-221 (2004).
22. Costa LG, Vitalone A, Cole TB, Furlong CE: Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69(4), 541-550 (2005).
23. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 107(5), 435-447 (2004).
24. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A: Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem. Biol. Interact. 137(2), 123-137 (2001).
25. Sedgwick JB, Hwang YS, Gerbyshak HA, Kita H, Busse WW: Oxidized low-density lipoprotein activates migration and degranulation of human granulocytes. Am.J Respir.Cell Mol. Biol. 29(6),702-709 (2003).
26. Mackness B, Davies GK, Turkie W et al.: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21(9), 1451-1457 (2001).
27. Ferre N, Camps J, Fernandez-Ballart J et al.: Regulation o f serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 49(9). 1491-1497 (2003).
28. Aviram M, Billecke S, Sorenson R et al.: Paraoxonase active site required for protection against LDL oxidation involves its free sulthydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18(10), 1617-1624 (1998).
29. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363(9410), 689-695 (2004).
30. Ranade K, Kirchgessner TG, lakoubova OA et al.: Evaluation of the paraoxonases as candidate genes for stroke: Gln 192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 36(11), 2346-2350 (2005).
31. Baum L, Ng HK, Woo KS et al.: Paraoxonase 1 gene Q 192R polymorphism affects stroke and myocardial infarction risk. Clin. Biochem. 39(3), 191-195 (2006).
32. American Thoracic Society: Standardization of Spirometry, 1994 Update. American Thoracic, Society. Am. J. Respir. Crit. Care Med. 152(3), 1107-1136 (1995).
33. Richards B, Skoletsky J, Shuber AP et al.: Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/ swabs. Hum. Mol. Genet. 2(2), 159-163 (1993).
34. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 3(1), 73-76 (1993).
35. Mackness B, Durrington P, Povey A et al.: Paraoxonase,and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 13(2), 81-88 (2003).
36. Cross CE, van der Viiet A, O'Neill CA, Louie S, Halliwell B: Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect. 102(Suppl. 10), 185-191 (1994).
37. Kinnula VL: Focus on antioxidant enzymes and antioxiclant strategies in smoking related airway diseases. Thorax 60(8), 693-700 (2005).
38. James RK, Leviev I, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101(19), 2252-2257(2000).
39. Erguder IB, Erguder T, Ozkan C et al.: Short-term effects of smoking cessation on blood antioxidant parameters and paraoxonase activity in healthy asymptomatic long-term cigarette smokers. Inhal. Toxicol. 18(8), 575-579 (2006).
40. LeVan TD, Koh WP, Lee HP, Koh D, Yu MC, London SJ: Vapor, dust, and smoke exposure in relation to adult-onset asthma and chronic respiratory symptoms: the Singapore Chinese Health Study. Am. J. Epidemiol. 163(2), 1118-1128 (2006).
41. Hoppin JA, Umbach DM, London SJ, Lynch CF, Alavanja MC, Sandier DP: Pesticides associated with wheeze among commercial pesticide applicators in the Agricultural Health Study. Am. J Epidemiol. 163(12), 1129-1137 (2006).
42. Hoppin JA, Umbach DM, London SJ, Alavanja MC, Sandier DP: Chemical predictors of wheeze among farmer pesticide applicators in the Agricultural Health Study. Am. J. Respir. Crit. Care Med. 165(5), 683-689 (2002).
43. Ozer EA, Pezzulo A, Shih DM et al.: Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253, 29-37(2005).
44. Stoltz DA, Ozer EA, Ng CJ et al.: Paraoxonase-2 dificiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L852-L860 (2007).
45. Alamoudi OS: Bacterial infection and risk factors in outpatients with acute exacerbation of chronic obstructive pulmonary disease: a 2-year prospective study. Respirology 12, 283-287 (2007).
46. Nseir S, Di Pompeo C, Cavestri B et al: Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit. Care Med. 34, 2959-2966(2006).